Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. We look forward to working on this new collaboration with Biohaven, a world leader in the clinical development of CGRP-targeted therapies.” TOKYO and CAMBRIDGE, England , Dec. Vlad Coric , M.D.,

Small Molecule 40

Small Molecule Licensing Licensing Clinical Trials 40

Drug Discovery World

APRIL 6, 2023

Ahead of attending the American Association for Cancer Research (AACR) annual meeting from 14-19 April, 2023 at the Orange County Convention Center in Orlando, Florida, DDW’s Megan Thomas outlines what to expect from the event. Programme highlights The topic tracks include everything from clinical trials, drug development, immunology and bioinformatics, (..)

Small Molecule 130

Small Molecule Targeted Protein Degradation Clinical Trials Engineering 130

Drug Discovery World

MAY 11, 2023

DDW’s Megan Thomas spoke with attendees, and comments on the event. Fundraising and investment Coming out of a global pandemic, in-person events initially added a degree of novelty to networking. At previous events, there has been an air of excitement but uncertainty of how quickly to adopt ‘business as usual’.

Targeted Protein Degradation 130

Targeted Protein Degradation Science Small Molecule Vaccine 130

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. Small molecule GLP1s?

Small Molecule 139

Small Molecule Trials Therapies Disease 139

Drug Discovery World

JUNE 14, 2023

We are a cell therapy company that uses a very specific receptor to engineer T cells and administer these engineered T cells back to solid tumour patients. We consider ourselves a next-generation engineered cell therapy company. There are a lot of successes that have been achieved with CAR T therapies.

Research 130

Research Engineering Therapies Small Molecule 130

Drug Discovery World

APRIL 8, 2024

Bold Therapeutics’ BOLD-100, a ruthenium-based small molecule, acts by targeting GRP78 to modulate the unfolded protein response (UPR) and by generating reactive oxygen species (ROS) leading to DNA damage and cell cycle arrest.

DNA 130

DNA Small Molecule Science Treatment 130

Drug Target Review

MAY 6, 2024

The clinical efficacy of BRAF inhibitors, like most other targeted cancer therapies, is inevitably limited by resistance development. We found that, indeed, cancer’s earliest defence mechanisms are triggered almost immediately after exposure to a targeted cancer therapy. What if our science can directly impact patients’ lives?”

Science 104

Science Therapies Small Molecule Clinical Trials 104

Drug Discovery World

JUNE 5, 2023

DDW’s Megan Thomas comments on the event. New approaches to partnering In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk.

Small Molecule 130

Small Molecule Treatment Science Disease 130

Drug Discovery World

APRIL 15, 2023

As the theme, Advancing the Frontiers of Cancer Science and Medicine , suggests, a number of announcements, results and presentations will take place at what is widely considered to be a flagship event for the cancer research community. Here are eight anticipated ‘curtain raisers’ in advance of the event: 1.

Virus 130

Virus Clinical Trials Trials Therapies 130

Drug Discovery World

APRIL 27, 2023

Pegcetacoplan, an injectable treatment, is the first medication to use targeted C3 therapy to diffuse the harmful three- pronged “complement cascade” triggered by GA, a physiological response that attacks and destroys healthy tissue. With these tools we can move very quickly from hit to lead in drug discovery.”

Small Molecule 130

Small Molecule Science Drugs FDA Approval 130

Drug Discovery World

NOVEMBER 1, 2022

Ground-breaking therapies . The company said: “As of the 28 September 2022, patients have been dosed with Auceliciclib, and dosing has completed for Cohorts 1 – 5 of the monotherapy dose escalation, and Cohorts 1a, 1b for the combination therapy arms with Temozolomide (TMZ).

Drugs 130

Drugs Science Therapies Clinical Trials 130

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding. Northern Ireland “Northern Ireland is a medtech super-hub,” says Saleko.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

The Pharma Data

NOVEMBER 8, 2021

“HER-MES is the first study that directly compared the therapeutic effects of an antibody and a small molecule in migraine prevention,” said Uwe Reuter, M.D., Additional study treatment-related adverse events reported by ?2% versus 38.9%). .” versus 38.9%). versus 31.2%).

Therapies 52

Therapies FDA Approval Small Molecule Treatment 52

Advarra

FEBRUARY 24, 2023

How do you know your experimental therapy is working? But what does “working” really mean when efficacy means something subjective, like quality of life, reduced psychiatric events, or less symptoms? All key questions to consider and address before the therapy even leaves the lab.

Clinical Trials 52

Clinical Trials Trials FDA Therapies 52

Drug Discovery World

APRIL 30, 2024

Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. For instance, consider how at the end of 2018, the mRNA therapies market was valued at $3.43 At the start of 2024, the first patients in a clinical trial investigating an mRNA cancer therapy were dosed.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

The Pharma Data

JANUARY 13, 2021

Preliminary analyses showed no clinically meaningful differences in safety results between the dexpramipexole and placebo groups, with no serious adverse events and 96% of subjects completing the primary assessment phase. Dexpramipexole was well tolerated by patients at all doses tested. President and CEO of Knopp. ABOUT ORAL DEXPRAMIPEXOLE.

Small Molecule 52

Small Molecule Trials Clinical Trials Treatment 52

Drug Target Review

JUNE 12, 2023

TEAD proteins are known to be very important in cancer progression TEAD proteins are known to be very important in cancer progression, and there are a number of therapies in development. Can you provide a summary of the key findings and implications of the preclinical studies on ISM6331 for the treatment of advanced solid tumours?

Metabolic Stability 92

Metabolic Stability Small Molecule Clinical Trials Pharmacokinetics 92

The Pharma Data

AUGUST 30, 2021

The head-to-head study was designed to directly compare the efficacy of abrocitinib 200mg versus dupilumab 300mg, in adult participants on background topical therapy with moderate to severe atopic dermatitis (AD). A larger percentage of patients treated with abrocitinib 200mg experienced adverse events compared to dupilumab 300mg.

Small Molecule 52

Small Molecule Trials Treatment FDA 52

The Pharma Data

JANUARY 5, 2021

The presentation will be webcast live and may be accessed from the Investor page of Relay’s website under Events and Presentations. Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process with the goal of bringing life-changing therapies to patients.

Small Molecule 52

Small Molecule Therapies Drugs 52

Dark Matter Blog

JULY 16, 2021

My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I was enticed by Arrakis’ founder Jen Petter to serve in one more operational role, leading the research group at Arrakis as the company launched as one of the first biotechs to target RNA with drug-like small molecules.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

Elrig

JUNE 4, 2024

The focus used to be more on small molecules, but we’re now starting to see antibody and cell therapeutics. All these ‘worlds’ can learn from each other – especially since the small molecule drug discovery process is much more mature than the antibody which is much more mature than the gene and cell therapy space.

Small Molecule 52

Small Molecule Science Drugs Research 52

The Pharma Data

OCTOBER 6, 2021

The adverse event profile was generally consistent with other clinical safety data for COMIRNATY. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. About Pfizer: Breakthroughs That Change Patients’ Lives.

Vaccine 52

Vaccine Small Molecule Government Therapies 52

The Pharma Data

APRIL 23, 2021

European Commission approves GSK’s JEMPERLI (dostarlimab), the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer. The approval makes dostarlimab the first anti-PD-1 therapy available for endometrial cancer in Europe. Hormone replacement therapy for endocrinopathies should be instituted as warranted.

Therapies 52

Therapies Treatment Licensing Licensing 52

The Pharma Data

NOVEMBER 29, 2020

1 Meanwhile, these MDM2 inhibitors present some challenges, including dose-limiting hematological toxicities, thus the urgent need to develop new generation of MDM2-targeting therapies in the treatment of cancer. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment.

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

The Pharma Data

JANUARY 17, 2021

The study enrolled 5,050 patients who received either vericiguat or placebo in combination with available heart failure therapies. HFrEF was formerly known as systolic heart failure. It is marked by the heart’s compromised ability to eject blood sufficiently during its contraction phase.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

OCTOBER 27, 2020

Mirati is advancing a novel pipeline to treat large patient populations across multiple programs and tumor types, including two programs, adagrasib and sitravatinib, in registration-enabling studies to treat non-small cell lung cancer (NSCLC). Forward-Looking Statements. View original content to download multimedia: [link]. Source link.

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

The Pharma Data

NOVEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. , (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in November.

Small Molecule 40

Small Molecule Clinical Trials Production Clinical Development 40

The Pharma Data

OCTOBER 25, 2020

In the study, the drug demonstrated statistically significant and clinically meaningful efficacy and a favorable adverse event and tolerability profile. The study is evaluating the safety and efficacy of CTX110, a wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell cancers. No serious adverse events were observed.

Vaccine 52

Vaccine Clinical Trials Trials Virus 52

The Pharma Data

JANUARY 3, 2021

Sixty-two percent of patients were treated with prior PD(L)-1 containing therapy, and the arms were well balanced. The frequency and severity of adverse events in the telaglenastat-treated population were comparable to that of cabozantinib alone. “We SOUTH SAN FRANCISCO, Calif., Median PFS was 9.2 months with cabozantinib and placebo.

Trials 52

Trials Small Molecule Clinical Trials Therapies 52

The Pharma Data

DECEMBER 13, 2020

RLY-1971 has the potential to serve as a backbone for combination therapy across numerous solid tumors and therefore represents an encouraging approach for cancer patients,” said Sanjiv Patel, M.D., In the event of regulatory approval of both RLY-1971 and GDC-6036 in combination, Relay Therapeutics is eligible to receive additional royalties.

Licensing 40

Licensing Licensing Clinical Trials Small Molecule 40

The Pharma Data

OCTOBER 1, 2021

Pfizer today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved CIBINQO ® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents aged 12 years and older with inadequate response to existing therapies.

Clinical Trials 52

Clinical Trials Small Molecule Trials Production 52

The Pharma Data

JANUARY 14, 2021

We believe that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate.

Small Molecule 52

Small Molecule Therapies Drug Development Drugs 52

Molecular Design

JUNE 8, 2023

Taking into account changes in their physicochemical properties over time, drugs are analyzed according to their target class, therapy area, and route of administration. Using ChEMBL version 26, a data set of 643 drugs acting on 271 targets was assembled, comprising 1104 drug−target pairs having ≥100 published compounds per target.

Cell Based Assays 75

Cell Based Assays Small Molecule Drugs Marketing 75

The Pharma Data

SEPTEMBER 12, 2020

The pivotal trial is event-based and there are many variables that will ultimately impact read-out timing. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. About Pfizer: Breakthroughs That Change Patients’ Lives.

Vaccine 52

Vaccine Trials Clinical Trials Small Molecule 52

The Pharma Data

JANUARY 18, 2021

The fireside chat will be available for 90+ days following the event at: [link] 5 69. Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers. . A live webcast of this presentation will be available for registered participants at: [link].

Small Molecule 40

Small Molecule Clinical Trials Trials Therapies 40

The Pharma Data

JANUARY 7, 2021

As CEO of Freeline, a liver-directed gene therapy company, she scaled the company from preclinical stage to a fully integrated biotechnology organization, which included a broad, internally developed pipeline, two programs in clinical development and a commercial-scale, high-quality CMC and manufacturing platform.

Small Molecule 52

Small Molecule Clinical Development Production Science 52